Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including storage, including long term storage, at ambient temperature. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disorder, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.
1. A pharmaceutical composition comprising a preparation of fecal bacteria in a lyophilized formulation comprising a cryoprotectant, wherein after at least 4 weeks of storage at room temperature, said preparation of fecal bacteria is capable of maintaining at least 50% cell viability relative to the initial cell viability immediately prior to storage, wherein said cryoprotectant is selected from the group consisting of trehalose, mannitol and sucrose, and wherein said preparation of fecal bacteria comprises a community of bacteria derived from a stool of one or more human donors.
2. The pharmaceutical composition of claim 1 , wherein after at least 4 weeks of storage at room temperature said preparation of fecal bacteria is capable of maintaining about 60% to about 80% cell viability relative to the initial cell viability immediately prior to said storage.
3. The pharmaceutical composition of claim 1 , wherein said cryoprotectant is mannitol.
4. The pharmaceutical composition of claim 1 , wherein said cryoprotecant is sucrose.
5. The pharmaceutical composition of claim 1 , wherein said cryoprotectant is trehalose and said trehalose is at a concentration of at least 2% in said lyophilized formulation.
6. The pharmaceutical composition of claim 1 , wherein said cryoprotectant is trehalose and said trehalose is at a concentration of at least 5% in said lyophilized formulation.
7. The pharmaceutical composition of claim 1 , wherein said cryoprotectant is trehalose and said trehalose is at a concentration of at least 10% in said lyophilized formulation.
8. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is for oral administration.
9. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is formulated as a geltab, pill, microcapsule, capsule, or tablet.
10. The pharmaceutical composition of claim 1 , wherein every 200 mg of said pharmaceutical composition comprises a pharmacologically active dose of microbes or spores selected from the group consisting of 10 3 to 10 14 , 10 4 to 10 14 , 10 5 to 10 14 , 10 6 to 10 14 , 10 7 to 10 14 , 10 8 to 10 14 , 10 4 to 10 13 , 10 5 to 10 12 10 6 to 10 11 , 10 7 to 10 10 , 10 8 to 10 9 , 10 3 to 10 13 , 10 3 to 10 12 , 10 3 to 10 11 , 10 3 to 10 10 , 10 3 to 10 9 , 10 3 to 10 8 , 10 3 to 10 7 , 10 3 to 10 6 , 10 3 to 10 5 , and 10 3 to 10 4 colony forming units (cfu) or total cell count.
11. The pharmaceutical composition of claim 1 , wherein said community of bacteria comprises cultured bacterial cells.
12. The pharmaceutical composition of claim 11 , wherein said cultured bacteria comprise a member of a genus selected from the group consisting of Lactobacillus, Bifidobacterium, Bacteroides, Clostridium, Eubacterium, Akkermansia, Alistipes, Faecalibacterium, Odoribacter , and Roseburia.
13. The pharmaceutical composition of claim 11 , wherein said cultured bacterial cells are derived from multiple of said one or more human donors.
14. The pharmaceutical composition of claim 1 , wherein said community of bacteria comprises uncultured bacterial cells.
15. The pharmaceutical composition of claim 14 , wherein said uncultured bacterial cells are derived from a single donor of said one or more human donors.
16. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is effective for treating one or more disorders selected from the group consisting of recurrent or primary C. difficile infection, autism spectrum disorder (ASD), ulcerative colitis, Crohn's disease, inflammatory bowel disease, and irritable bowel syndrome.
17. An oral pharmaceutical composition comprising a non-selective preparation of fecal bacteria in a lyophilized formulation comprising cryoprotectant, wherein, after at least 4 weeks of storage at room temperature, said preparation of fecal bacteria is capable of maintaining at least 50% cell viability relative to the initial cell viability-immediately prior to said storage, and is effective for treating one or more disorders or conditions selected from the group consisting of recurrent or primary C. difficile infection, autism spectrum disorder (ASD), ulcerative colitis, Crohn's disease, inflammatory bowel disease and irritable bowel syndrome, and wherein said cryoprotectant is selected from the group consisting of trehalose, mannitol and sucrose.
18. The pharmaceutical composition of claim 17 , wherein said lyophilized formulation further comprises an amino acid.
19. The pharmaceutical composition of claim 17 , wherein said cryoprotectant is mannitol.
20. The pharmaceutical composition of claim 17 , wherein said cryoprotectant is trehalose and said trehalose is at a concentration of at least 2% in said lyophilized formulation.
21. The pharmaceutical composition of claim 17 , wherein said cryoprotectant is also a lyoprotectant.
22. The pharmaceutical composition of claim 17 , wherein said cryoprotectant is sucrose.